Answers are grounded in this paper and cite their sources.
The prevention and control of vector-borne diseases is a priority for improving global health. Despite recent advances in the characterization of ectoparasite-host-pathogen molecular interactions, vaccines are not available for most ectoparasites and vector-borne diseases that cause millions of deaths yearly. In this paper, in response to the question of why new vaccines for the control of ectoparasite vectors have not been registered and commercialized, and to contribute developing new effective vaccines against ectoparasite vectors, we propose challenges and approaches to be addressed.
No takes yet. Share an insight, caveat, or question.
Fuente et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: